Gilead Sciences’ Sovaldi for Hepatitis C. (Photo credit: Bob Ecker/MCT/Newscom)
“We have millions of people who need treatment for hepatitis C and payers obviously don’t have the budget to cover this tremendous expense,” Jagpreet Chhatwal, the study’s lead author and an assistant professor of health services research at the The University of Texas M.D. Anderson Cancer Center said.
